MBX Biosciences, Inc.
MBX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001776111
In the last 90 days, MBX Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $3.06B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:19 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 7, 2025 |
| Operating expenses | $98.1M | $68.2M |
| Research and development | $79.2M | $57.4M |
| Selling, general and administrative | $18.9M | $10.8M |
| Operating income | -$98.1M | -$68.2M |
| Income tax | $0 | $0 |
| Net income | -$87.0M | -$61.9M |
| EPS, basic | $-2.38 | $-5.82 |
| EPS, diluted | $-2.38 | $-5.82 |
| Weighted shares, basic | 36.5M | 10.6M |
| Weighted shares, diluted | 36.5M | 10.6M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 7, 2025 |
| Cash and equivalents | $75.3M | $49.4M |
| Short-term investments | $298.4M | $212.8M |
| Total current assets | $381.5M | $267.3M |
| Property, plant and equipment | $2.73M | $1.08M |
| Total assets | $385.1M | $268.5M |
| Accounts payable | $2.98M | $5.33M |
| Total current liabilities | $15.5M | $11.1M |
| Total liabilities | $15.9M | $11.1M |
| Shareholders' equity | $369.2M | $257.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 7, 2025 |
| Operating cash flow | -$79.9M | -$54.7M |
| Capital expenditures | $1.93M | $874.0K |
| Free cash flow | -$81.9M | -$55.6M |
| Stock-based compensation | $8.68M | $5.22M |
| Investing cash flow | -$83.7M | -$160.6M |
| Financing cash flow | $189.6M | $234.1M |
| Net change in cash | $25.9M | $18.8M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.